financetom
Business
financetom
/
Business
/
BASF sells majority of coatings business to Carlyle, Qatar Investment Authority
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BASF sells majority of coatings business to Carlyle, Qatar Investment Authority
Oct 10, 2025 5:32 AM

FRANKFURT Oct 10 (Reuters) - BASF has agreed

to sell a majority stake in its coatings business to private

equity firm Carlyle and the Qatar Investment Authority,

valuing the unit at 7.7 billion euros ($8.91 billion).

In a joint statement, the companies said on Friday that BASF

would retain a 40% stake in the coatings business and that it

would also receive a pre-tax cash inflow of about 5.8 billion

euros on completion of the transaction.

BASF put the coatings division up for sale at the start of

the year, part of a wider strategy to focus on businesses that

are closely integrated and physically connected within its major

chemical plants across the globe.

BASF said that the transaction - when combined with the sale

earlier this year of its decorative paints business to

Sherwin-Williams ( SHW ) - values BASF's entire coatings division at an

enterprise value including debt of 8.7 billion euros, or about

13 times 2024 earnings before interest, tax, depreciation and

amortisation (EBITDA).

The chemical company started approaching the market in the

second quarter to explore strategic options for its remaining

coatings activities, and was targeting a decision in the last

quarter of the year.

It has said proceeds from a potential divestment could

enable an earlier start to a previously announced share buyback

of at least 4 billion euros between 2027 and 2028.

($1 = 0.8642 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Napco Security Technologies Fiscal Q2 Earnings, Net Sales Fall
Napco Security Technologies Fiscal Q2 Earnings, Net Sales Fall
Feb 3, 2025
07:15 AM EST, 02/03/2025 (MT Newswires) -- Napco Security Technologies ( NSSC ) reported fiscal Q2 earnings Monday of $0.28 per diluted share, down from $0.34 a year earlier. Two analysts polled by FactSet expected $0.33. Net sales for the quarter ended Dec. 31 were $42.9 million, compared with $47.5 million a year earlier. Analysts surveyed by FactSet expected $49.9...
Alliance Resource Partners' Q4 Earnings, Revenue Fall
Alliance Resource Partners' Q4 Earnings, Revenue Fall
Feb 3, 2025
07:15 AM EST, 02/03/2025 (MT Newswires) -- Alliance Resource Partners ( ARLP ) reported Q4 earnings Monday of $0.12 per diluted limited partner unit, down from $0.88 a year earlier. Analysts polled by FactSet expected $0.61. Revenue for the quarter ended Dec. 31 was $590.1 million, compared with $625.4 million a year earlier. Analysts surveyed by FactSet expected $633.6 million....
Eat & Beyond Acquires Milo Media Technologies for $2.8 Million in Shares
Eat & Beyond Acquires Milo Media Technologies for $2.8 Million in Shares
Feb 3, 2025
07:08 AM EST, 02/03/2025 (MT Newswires) -- Eat & Beyond Global Holdings ( EATBF ) over the weekend said it will acquire Milo Media Technologies in an all-shares transaction valued at $2.8 million. The company will issue 15 million shares at $0.185 each, along with 15 million two-year warrants to Milo Media. Each warrant can buy an additional share at...
Pfizer Says Metastatic Colorectal Cancer Combination Therapy Shows Significant Survival Benefit
Pfizer Says Metastatic Colorectal Cancer Combination Therapy Shows Significant Survival Benefit
Feb 3, 2025
07:06 AM EST, 02/03/2025 (MT Newswires) -- Pfizer ( PFE ) said Monday its phase 3 study of Braftovi combination regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients with a type of metastatic colorectal cancer. The company said Braftovi, in combination with cetuximab and mFOLFOX6, also showed a significant improvement in overall survival compared...
Copyright 2023-2026 - www.financetom.com All Rights Reserved